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1. Introduction
While the genetic component of Autism Spectrum Disorders (ASD) has been clearly estab‐
lished from various lines of study, the multitude of genes and chromosomal loci associated
with ASD has made identification of the underlying molecular mechanisms of pathogenesis
difficult to resolve. A range of diverse methodologies and study types have identified both
rare and common genetic variants in ASD candidate genes and chromosomal loci. Moreover,
the recent development of high-throughput next generation sequencing (NGS) technologies
and the increasing usage of chromosomal microarray analysis (CMA) has led to a significant
expansion in the number of single nucleotide variants (SNVs) and copy number variants
(CNVs) potentially affecting one or more genes that have been identified in ASD individuals.
This, in turn, has given critical insight into the molecular and cellular processes that may be
preferentially targeted for disruption by genetic lesions in ASD patients.
However, it is important to note that there is no genetic test available for the diagnosis of ASD.
Rather, genetic testing is primarily aimed at identifying genetic variants potentially responsi‐
ble for disease pathogenesis in a given individual diagnosed with ASD. Furthermore, the
utility of NGS and CMA in genetic evaluation of ASD individuals is dependent on proper
interpretation and reporting of test results. In this chapter we will discuss 1) genetic testing
technologies currently available for the identification of genetic variation in ASD cases, 2) the
genes and genomic loci targeted by single nucleotide and copy number variants that have been
linked to ASD susceptibility, 3) the bioinformatics tools that enable researchers to process the
enormous amount of genetic data associated with ASD, and 4) challenges that exist in the
interpretation and reporting of genetic evaluation results in ASD cases.
© 2013 Larsen et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Genetic screening technologies for the evaluation of ASD cases
Autism spectrum disorders (ASD) are among the most highly heritable neurodevelopmental
disorders, and extensive research has been focused on identifying the underlying genetic ba‐
sis of these disorders. It has become apparent that ASD is a genetically heterogeneous disor‐
der, with hundreds of genes and chromosomal rearrangements identified that confer
varying degrees of risk for disease. Initially, susceptibility genes and genomic loci were
identified by costly, low-throughput techniques, such as automated Sanger sequencing and
conventional cytogenetic techniques. The need for lower-cost, higher-throughput genetic
screening technologies capable of identifying genome-wide variation in individuals with ge‐
netically complex diseases, such as ASD, has driven improvements in pre-existing techni‐
ques and the development of new technologies. The genetic screening technologies
presently available to clinical geneticists and researchers are capable of providing lower-
cost, high-throughput genetic data that have significantly expanded our knowledge of ge‐
netic variation, both in the general population and in ASD individuals in particular. The first
major high-throughput studies aimed at identifying CNVs and SNVs in ASD cohorts were
published in 2010 and 2011, respectively [1, 2]. Here we describe in greater detail two of
these genetic screening technologies that have become widely used in the genetic evaluation
of ASD cases: next generation sequencing (NGS) and chromosomal microarray (CMA).
2.1. Next generation sequencing
Next-generation sequencing (NGS) is a term used to describe a collection of high-through‐
put sequencing technologies that have enabled clinicans to screen larger amounts of genetic
material at lower cost than traditional sequencing technologies, such as automated Sanger
sequencing [3]. NGS is typically used to identify single nucleotide variants (SNVs), as well
as small insertions or deletions in candidate genes. However, NGS can also be used to iden‐
tify copy number variants (CNVs), as was recently demonstrated in a report detailing whole
exome sequencing in a cohort of ASD cases [4], as well as balanced chromosomal rearrang‐
ments, which are typically not detected by genome-wide microarrays [5, 6]. Since 2011, six
research articles have been published that have identified rare variants in both existing and
novel ASD susceptibility genes using NGS techniques [2, 4, 7-10], a fact that illustrates how
extensively these techniques have been adopted by the ASD research community. As a re‐
sult of these studies, the potential number of potential ASD-linked genes have increased
dramatically (Table 1). Furthermore, as demonstrated by the minimal overlap of candidate
genes across these studies, the results of these studies further illustrate the genetic heteroge‐
neity of ASD.
NGS techniques are typically divided into three categories, each with its own advantages
and disadvantages (summarized in Table 2). These techniques vary in terms of genetic cov‐
erage (the size of the sequenced target, which can range in size from one or a few genes to
the entire genome) and genetic resolution (sensitivity in detection of variants per sequencing
target). In general, the smaller the genetic coverage, the higher the genetic resolution. It
should be noted that, as the size of the target for sequencing increases, so does the number
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of both false-positive and false-negative variants [11]; this is one of the many considerations
that must be taken into account in deciding which NGS technique to utilize.
Exome Report Total # of genes # of unique genes # of overlapping genes
O'Roak 2011 21 21 0
Sanders 2012 170 166 4
O'Roak 2012 240 227 13
Neale 2012 173 168 5
Chahrour 2012 53 53 0
Iossifov 2012 363 338 25
Total 1020 973 47
Table 1. Six recent scientific articles describing rare genetic variants identified in ASD cases by next generation
sequencing (NGS) has led to a dramatic increase in the number of potential ASD candidate genes and further
illustrates the genetic heterogeneity of ASD. Overlapping genes are genes in which a rare variant was identified in
more than one exome report and are used as a measure of genetic heterogeneity.
Availability Cost Advantages Disadvantages
Targeted gene
panels
Commercially
available
~$5000 -Highest resolution of NGS
approaches
-Contains a number of well-
characterized ASD
susceptibility genes
(syndromic and non-
syndromic)
-Unable to detect variants
in genes not included in the
panel
Whole exome
sequencing
Available only in
research settings
~$1000 -Estimated to detect the
majority of disease-
covering variants
-Unable to detect variants
in non-coding regions
Whole
genome
sequencing
Available only in
research settings
~$4000-$5000 -Greatest coverage of the
genome (both coding and
non-coding regions)
-Lowest resolution of NGS
techniques
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Availability Cost Advantages Disadvantages
-Higher cost than whole
exome sequencing
Table 2. A summary of the benefits and drawbacks of the three types of next generation sequencing (NGS) techniques in
the genetic evaluation of ASD cases. Cost estimates of whole-exome and whole-genome sequencing in [14].
2.1.1. Targeted gene panels
Targeted gene panels generally test for 50-100 genes that have been demonstrated to be strong‐
ly associated with a particular disease. Such gene panels are already extensively used to screen
individuals for a wide range of cancers and inherited diseases for which causative genes have
been identified. A number of commercially-available ASD gene panels have recently been de‐
signed to target both genes strongly associated with non-syndromic ASD as well as syndromic
genes (genes that cause syndromes in which a subset of affected individuals also develop ASD,
such as FMR1, MECP2, and CACNA1C, which cause Fragile X, Rett, and Timothy syndromes,
respectively). For example, the Greenwood Genetic Center offers a 62-gene syndromic gene
panel that covers the coding region and flanking intronic boundaries of ASD-linked 62 genes
for  $5500  (http://www.ggc.org/images/pdfs/syndromicautism62-genengspanel.pdf).  While
targeted gene panels offer the smallest coverage of the human genome of the three NGS ap‐
proaches, they offer the highest resolution. One of the major drawbacks to the use of targeted
gene panels for a genetically heterogeneous disorder such as ASD is the inability to detect mu‐
tations in genes outside of those included in the gene panel.
2.1.2. Whole exome sequencing
Whole exome sequencing, which is also known as targeted exome capture, is designed to spe‐
cifically identify variants in protein-coding regions of the human genome. Although these pro‐
tein-coding regions, called exons, constitute a very small percentage of the human genome, it is
estimated that they contain up to 85% of disease-causing mutations [12, 13]. However, whole
exome sequencing will fail to detect any potentially pathogenic variants in non-coding regions
of the human genome. This NGS method also provides lower resolution than targeted gene
panels. Nonetheless, whole exome sequencing is increasingly being used to identify potential‐
ly pathogenic rare single gene variants in individuals with ASD [2, 4, 7-10].
2.1.3. Whole genome sequencing
In contrast to whole exome sequencing, which only covers protein-coding regions of the
human genome, whole genome sequencing provide coverage of the entire genome, allowing
for the sequencing of both coding and non-coding genomic regions. As such, single nucleotide
changes and small insertions/deletions within non-coding regions of the genome can be
detected by this method. While whole genome sequencing covers the largest amount of the
human genome of all NGS techniques, it offers the lowest resolution of the three NGS
technologies. Whole genome sequencing is also more costly than whole exome sequencing,
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although the differences in cost betwen these two techniques have fallen from 10- to 20-fold
[13] to 4- to 5-fold [14].
2.2. Chromosomal microarray
Microscopically-visible chromosomal rearrangments have long been implicated in the onset
and pathogenesis of neurodevelopmental disorders, includng ASD. Indeed, many of the most
strongly ASD-linked chromosomal deletions and duplications, collectively referred to as copy
number variants (CNVs), were discovered through the use of conventional cytogenetic
techniques such as G-banded karyotyping, fluorescent in situ hybridization (FISH), and
microsatellite analysis. For example, duplications of chromosome 15q11-q13 were first
implicated in ASD in the mid-1990s by these methods [15-17]. Likewise, these methods
identified chromosomal rearrangments on the long arm of chromosome 22 in ASD cases [18,
19]. However, conventional cytogenetic techniques are impractical in the identification of copy
number variation throughout the human genome in large case cohorts. While G-banded
karyotyping is capable of detecting large chromosomal deletions and duplications (~1 Mb and
larger), it lacks the sensitivity to detect smaller CNVs. Alternatively, the use of techniques such
as FISH is generally limited to screen a particular chromosomal region, so while they are useful
for examining copy number variation in a genomic loci of interest in larger case populations,
they are impractical for the purposes of identifying deletions and duplications throughout the
genome.
In the last decade, technological and computational advances have allowed clinical geneticists
and researchers to detect submicroscopic chromosomal deletions and duplications throughout
the human genome in large case cohorts that would not be detected by traditional cytogenetic
techniques. Chromosomal microarray (CMA) is a term frequently used to include all types of
array-based whole genome copy number analyses, with the two most widely used being array-
comparative genomic hybridization (aCGH) and single nucleotide polymorphism (SNP)
arrays. CMA has been demonstrated to provide a higher diagnostic yield than G-banded
karyotyping (15-20% compared to ~3%) due to its ability to detect submicroscopic deletions
and duplications, and it has been proposed that CMA should replace conventional cytogenetic
techniques as a first-tier diagnostic tool for individuals with congential abnormalities and
developmental disorders, including ASD [20]. High-throughput genome-wide aCGH and SNP
arrays are now regularly used in the detection of CNVs in large ASD cohorts [1, 21-24].
aCGH and SNP arrays employ similar methodologies in the detection of CNVs (Figure 1). The
first step involves labeling the DNA of the ASD patient with a fluorophore, thereby creating
a test sample. The test sample is then mixed with an equal amount of DNA from a normal
reference sample that has been labeled with a different fluorophore. This mixed DNA sample
is added to a glass slide containing thousands of oligonucleotide probes corresponding to
different chromosomal regions that cover the human genome; in the case of SNP arrays, the
oligonucleotide probes are specific for common polymorphisms found in the general popu‐
lation. The sensitivity of CMA has been greatly increased in recent years by the development
of arrays employing a larger number of smaller oligonulceotide probes; in doing so, clinical
geneticists and researchers are able to detect even smaller copy number changes than before
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without compromising genomic coverage. The test and reference DNA samples hybridize with
the probes on the slide, and the fluorescence intensities of the test and reference DNA can then
be measured. Following analysis with software that is typically specific for the platform being
used, one or more algorithms are used to call the CNV. The ratio between the two fluorescence
intensities is used to identify copy number changes. For example, if the test-to-reference ratio
is 1 (yellow in the example below), then there is no change in copy number at the chromosomal
region corresponding to a given probe, If the test-to-reference fluorescence ratio is > 1 for a
particular probe (green in the example below), then the ASD patient carries a duplication in
the chromosomal region corresponding to that probe. If the test-to-reference ratio is < 1 (red
in the example below), then the patient carries a deletion at that site of the genome.
Figure 1. Chromosomal microarray (CMA) analysis involves hybridization of differently labeled test and reference DNA
samples with oligonucleotide probes, followed by computerized analysis and identification of copy number variants
(CNVs) based on changes in fluorescence intensity ratio.
Despite the recommended use of CMA as a first-tier genetic evaluation tool in place of conven‐
tional cytogenetic techniques, it should be noted that aCGH is unable to detect balanced chro‐
mosomal rearrangments and other chromosomal abnormalities that have traditionally been
detected by karyotype analysis [25]. In addition to their traditional utilization in the detection
of risk-conferring common polymorphisms, SNP arrays have the added advantage of being
able to detect copy number neutral genetic variation such as uniparental disomy and long con‐
tiguous streteches of homozygosity (LCSH) that cannot be detected by aCGH [25, 26].
3. Genetic variation in ASD
With the advent of NGS techniques and increasing usage of CMA screening, the number of
SNVs and CNVs that have been identified in ASD individuals has grown significantly. Based
on a survey of recently published exome sequencing studies of ASD cohorts, it was estimated
that the number of dosage-sensitive ASD susceptibility genes is approximately 370, with
roughly a third of these genes having been identified [10]. However, even this number might
be a conservative projection. As shown in Figure 2, the number of ASD susceptibility genes in
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the Human Gene Module of the autism genetic database AutDB [27] has increased from 284
genes in September 2011 to 369 genes in June 2012. A large number of newer susceptibility
genes have been annotated from reports employing whole exome sequencing of ASD cases [2,
4, 7-10], illustrating the increasing usage of NGS techniques in the study of genetic variation
in ASD. In addition to the identification of novel ASD susceptibility genes, NGS techniques
have identified novel rare variants in previously identified ASD susceptibility genes. The
number of ASD-associated CNV loci has also increased significantly, with the CNV module
of AutDB expanding from 1034 CNV loci in September 2011 to 1173 loci in June 2012 (Figure
2). In this section we describe the genetic categories into which ASD susceptibility genes have
been classified, as well as describe recent studies that have yielded invaluable insight on the
functional profiles of ASD-associated genes and CNV loci.
Figure 2. The number of genes and CNV loci associated with ASD in the genetic database AutDB has increased over
the last four quarterly release dates.
3.1. Genetic categories of ASD susceptibility genes
The earliest ASD susceptibility genes were rare single gene variants in genes associated with
syndromes such as Fragile X syndrome and Rett syndrome. The discovery of single gene
mutations/disruptions in two neuroligin genes, NLGN3 and NLGN4, in ASD siblings [28]
initiated the search for additional ASD susceptibility genes in non-syndromic ASD cases. The
continued identification of rare genetic variants associated with both syndromic and non-
syndromic ASD, as well as of risk-conferring polymorphisms enriched in ASD populations
Genetic Evaluation of Individuals with Autism Spectrum Disorders
http://dx.doi.org/10.5772/53900
197
compared to unaffected controls in genetic association studies, has led to significant increases
in the number of ASD-linked genes. While the majority of ASD-associated genes have been
linked to disease on the basis of genetic studies in human populations, a number of additional
ASD-linked genes have been identified by alternate methodologies, such as gene expression
studies in post-mortem brain tissue of ASD individuals.
ASD susceptibilty genes in the Human Gene Module of AutDB are defined into four distinct
categories:
1. Rare. This category features genes implicated in rare monogenic forms of non-syndromic
ASD. Rare allelic variants within this category include single nucleotide variants, small
insertions and deletions, chromosomal rearrangements such as translocations and inversions,
and monogenic submicroscopic deletions and duplications. Among the genes within this
category are CACNA1H and SHANK1.
2. Syndromic. Syndromic genes were among the first genes for which rare genetic variants
linked to autism were identifed. In addition to well-characterized syndromic genes such as
FMR1 (Fragile X syndrome), MECP2 (Rett syndrome), and CACNA1C (Timothy syndrome),
genes such as CHD7 and SLC9A6 fall into the syndromic category.
3. Association. This category includes genes in which small risk-conferring common poly‐
morphisms have been identified from genetic association studies in idiopathic ASD popula‐
tions. Among the genes within this category are MET and MTHFR.
4. Functional. This category includes functional candidate genes that have not yet been
experimentally linked to ASD by genetic studies. Among the genes in this category are BCL2
and PDE4B, whose inclusion is based on changes in gene expression in post-mortem brain
tissue of ASD subjects.
As shown in Figure 3, while the number of both rare and common ASD-associated variants in
the Human Gene module of AutDB has increased over the last four quarterly release dates,
the number of rare variants has increased at a much greater rate than the number of common
variants. The number of rare variants increased from 1141 in September 2011 to 1675 in June
2012, an increase of ~146%. In contrast, the number of common variants rose form 508 to 575
over the same span of time, an increase of only ~113%. This disparity between the addition of
rare and common variants to AutDB is in part due to the increased usage of NGS and CMA
and subsequent identification of rare ASD-associated variants in large ASD cohorts.
It should be noted that a given gene can fall under multiple genetic categories, depending on
the affected population under investigation and the type of study. For example, both rare
variants and risk-conferring common polymorphisms have been identified in the CNTNAP2
gene in ASD individuals across multiple studies [2, 29-31] However, in addition to its role as
an ASD susceptibility factor, recent studies suggest that rare variants in CNTNAP2 are
responsible for two additional syndromes: cortical dysplasia-focal epilepsy syndrome [32] and
Pitt-Hopkins-like syndrome 1 [33]. Therefore, based on the combined evidence from all of these
aforementioned studies, CNTNAP2 is classified in AutDB as a syndromic gene, a rare gene,
and an association gene.
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The classification of ASD-linked genes into genetic categories is a useful tool in assessing the
strength of the evidence for the connection of a given gene with ASD. Genes within the rare
and syndromic categories are generally considered to have the strongest link to ASD [34]. Due
to the frequent lack of replication in their association with ASD from one study to the next,
genes within the association category are considered to have a weaker link to ASD than genes
within the rare and syndromic categories. Genes within the functional category have no direct
documented connection to ASD and are therefore considered to be among the weakest ASD
candidate genes.
Figure 3. The number of rare and common ASD-associated variants in the Human Gene module of AutDB has in‐
creased over the last four quarterly release dates.
3.2. Functional profiles of ASD-associated genes and CNV loci
The increasing number of ASD-associated genetic factors, as shown in Figure 2, has only added
to the well-established genetic heterogeneity of ASD. In spite of the complexity caused by this
genetic heterogeneity, bioinformatic analysis of ASD-linked genes and CNV loci has yielded
valuable insight into the molecular interactions and cellular pathways preferentially targeted
by genetic lesions in individuals with ASD. Not only can this information be potentially used
to design therapeutic approaches targeting disrupted pathways, but it can also aid in assessing
the clinical importance of newly-discovered ASD candidate genes and CNV loci in which
pathogenic variants are identified by NGS and CMA, respectively. For example, a gene whose
encoded gene product resides within a known ASD-associated cellular process or interacts
with a known ASD-associated gene is a stronger candidate than a gene that fails to reside
within known ASD-associated cellular processes or interact with known ASD-associated
genes.
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Recent large-scale ASD genetic studies have used a systems biology approach to translate ge‐
netic information into functional profiles that shed light on how genetic variation in ASD may
lead to disease onset and pathogenesis. Rare CNVs identified in large ASD cohorts have been
shown to be enriched for genes involved in cellular processes of relevance for ASD, including
cellular proliferation, projection, and motility, and GTPase/Ras signaling [1], neuronal cell ad‐
hesion and ubiquitin-mediated degradation [22], glycobiology [35], axon growth and path‐
finding  [36],  and  synapse  development,  axon  targeting,  and  neuron  motility  [37].  Gene
datasets from genome-wide association studies in ASD populations were demonstrated to be
enriched for Gene Ontology (GO) classifications for cellular processes including pyruvate me‐
tabolism, transcription factor activation, cell signaling and cell-cycle regulation [38]. A recent
report describing gene pathway analysis using single nucleotide polymorphism (SNP) data
from the Autism Genetics Research Exchange (AGRE) identified cellular pathways such as cal‐
cium signaling, long-term depression and potentiation, and phosphotidylinositol signaling
that reached statistical significance in both Central European and Han Chinese populations
[39]. More recently, whole exome sequencing studies in large ASD cohorts have demonstrated
that proteins encoded by genes in which potentially disruptive de novo mutations were identi‐
fied showed a higher degree of connectivity among themselves and to previously identified
ASD genes based on protein-protein interaction network analysis [4, 8]. Another exome se‐
quencing study in ASD individuals found that many of the genes in which potentially disrup‐
tive variants were identified associated with the Fragile X Mental Retardation Protein (FMRP),
the encoded product of the syndromic ASD gene FMR1 [10]. Taken together, these functional
maps suggest that specific cellular pathways and processes are preferentially targeted by ge‐
netic variation in ASD cases, and that association with the encoded products of well-character‐
ized ASD-linked genes offers evidence for pathogenic relevance.
Knowledge of ASD-associated genes can also be used to identify novel ASD candidate genes.
Following the construction of functional and expression profiles from a reference set of 84 rare
and syndromic ASD-linked genes, we generated a predictive map of novel ASD candidate
genes [40]. In total, 460 potential candidate genes were identified that overlapped both the
functional profile and the brain expression profile of the initial reference set. The power of this
predictive gene map was demonstrated by the capture of 18 pre-existing ASD-associated genes
that were not included in the reference gene dataset, with the remaining 442 genes serving as
novel ASD candidate genes. Since the publication of our predictive gene map, 12 of the novel
ASD candidate genes identified in [40] have been added to AutDB, demonstrating the
continued power of this analysis (manuscript in preparation).
4. Bioinformatics of ASD
With the rapid growth of genetic data obtained from ASD individuals, there has become a
critical need for databases specializing in the storage and assessment of this data. Here we
highlight several of the ASD-related genetics databases that are available to researchers.
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4.1. AutDB
Our  autism  database  AutDB  (http://autism.mindspec.org/autdb/Welcome.do)  is  a  web-
based, searchable database of ASD candidate genes identified in genetic association stud‐
ies,  genes  linked  to  syndromic  autism,  and  rare  single  gene  mutations  [27].  Evidence
regarding ASD candidate genes is  systematically extracted from peer-reviewed,  primary
scientific  literature and manually curated by our researchers for inclusion in AutDB. To
provide  high-resolution  view of  various  components  linked  to  ASD,  we  developed  de‐
tailed annotation rules based on the biology of each data type and generated controlled
vocabulary  for  data  representation.  AutDB is  widely  used by  individual  laboratories  in
the ASD research community, as well as by consortiums such as the Simons Foundation,
which licenses it as SFARI Gene.
AutDB is designed with a systems biology approach, integrating genetic information with‐
in the original Human Gene module to corresponding data in subsequent Animal Model,
Protein Interaction (PIN) and Copy Number Variant (CNV) modules. The Animal Model
module contains a comprehensive collection of mouse models linked to ASD [41]. While
the Animal Model module initially contained only genetic mouse models of ASD, it  has
since been expanded to include induced mouse models of ASD in which a chemical or bi‐
ological agent linked to ASD has been administered. As core behavioral features of ASD
such as social interactions and communications can only be approximated in animal mod‐
els, the annotation strategy for this module includes four broad areas: 1) core behavioral
features of ASD, 2) ASD-related traits such as seizures and circadian rhythms that are her‐
itable and more easily quantified in animal models;  3)  neuroanatomical  features,  and 4)
molecular profiles. To this end, we developed PhenoBase, a classification table for system‐
atically annotating models with controlled vocabulary containing 16 major categories and
>100 standardized phenotype terms. The PIN module of AutDB serves as a repository for
all  known protein interactions of  ASD candidate genes,  documenting six major types of
direct  interactions:  1)  protein binding,  2)  promoter binding,  3),  RNA binding,  4)  protein
modification, 5) direct regulation, and 6) autoregulation. Its content is envisioned to have
immediate  application  for  network  biology  analysis  of  molecular  pathways  involved in
ASD  pathogenesis.  For  the  purposes  of  genetic  evaluation  of  individuals  with  ASD,
knowledge of the protein interactions of ASD-associated genes can potentially aid in the
clinical  assessment  of  novel  ASD  candidate  genes  based  on  their  interactions,  or  lack
thereof, with known ASD-linked genes.
4.2. Gene scoring module of SFARI gene
As previously mentioned, AutDB is licensed to the Simons Foundation as SFARI Gene.
However, unlike AutDB, SFARI Gene includes a unique feature initiated by the Simons
Foundation called the Gene Scoring module (https://gene.sfari.org/autdb/GS_Home.do). The
Gene Scoring module is a web-based platform detailing the rank of ASD-associated genes in
the SFARI Gene Human Gene module [42]. With the increase in the number of genes linked
to ASD, a Gene Scoring initiative was launched to assess the ASD candidate genes based on a
set of standardized annotation rules. Following evaluation by an expert panel of advisors, the
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gene assessment results are then integrated in the form of Gene Score Cards to display the
scores and the evidence in a graphical user interface for the ASD-linked gene. Recently, a
community-wide annotation functionality was incorporated into the Gene Scoring module,
allowing users to download the Gene Scoring dataset, score genes of their choice, and submit
their scores to SFARI for possible inclusion.
4.3. DECIPHER
DECIPHER (Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl
Resources) (http://decipher.sanger.ac.uk/) is an interactive web-based database that incorpo‐
rates a suite of tools designed to aid in the interpretation of submicroscopic chromosomal
deletions and duplications [43]. Genetic and phenotypic information is publically available
not only for individuals diagnosed with idiopathic ASD, but also for individuals diagnosed
with a recognized microdeletion or microduplication syndrome in which a subset of affected
individuals also develop ASD.
4.4. AutismKB
AutismKB (http://autismkb.cbi.pku.edu.cn/) is a web-based, searchable database hosted by the
Center for Bioinformatics, Peking University [44]. AutismKB is an evidence-based knowledge
resource for ASD genetics containing information on genes, copy number variants, and linkage
regions associated with ASD. Analysis of the gene content in AutismKB is available for users
in the form of GO term enrichment analysis using the DAVID functional annotation tool and
pathway enrichment analysis. Much like the Gene Scoring Module of SFARI Gene (see section
4.2), the genes within AutismKB are scored.
4.5. Autism Chromosome Rearrangement Database
The Autism Chromosome Rearrangement Database (http://projects.tcag.ca/autism/) is a web-
based, searchable genetic database of chromosomal structural variation in ASD that is hosted
by The Centre for Applied Genomics at the Hospital for Sick Children in Toronto, Canada [21].
The content of this database, which is derived both from published research articles and in-
house experimental results, includes cytogenetic and microarray data from individuals with
ASD.
4.6. Autism Genetic Database
The Autism Genetic Database (http://wren.bcf.ku.edu/) is a web-based, searchable genetic
database developed by researchers at the University of Kansas [45]. In addition to ASD-
associated genes and CNVs, this database also includes information on known non-coding
RNAs and chemically-induced fragile sites in the human genome.
Recent lines of evidence have placed non-coding RNAs under increased scrutiny with regards
to their potential pathogenic role in ASD. A number of small nucleolar RNAs (snoRNAs) reside
within the ASD-associated 15q11-q13 region. A mouse model engineered to mimic duplication
of the 15q11-q13 region observed in ~1% of ASD cases exhibited overexpression of the snoRNA
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MBII52 (the mouse ortholog of the human snoRNA HBII52), which could potentially alter
serotonergic signaling and contribute in part to the ASD-associated traits exhibited by these
mice [46]. More recently, it was discovered that a non-coding RNA is transcribed from a gene-
poor region of chromosome 5p14.1 identified in genome-wide association studies of ASD
cohorts [47]. Expression of the non-coding RNA, designated MSNP1AS, was shown to be
higher both in individuals carrying the ASD-associated T allele and in post-mortem brain
tissue of individuals with ASD.
Spontaneous breakage during DNA replication at rare chromosomal fragile sites may also play
a role in the pathogenesis of neuropsychiatric disorders such as ASD. The chromosomal fragile
site FRAXA has been implicated in fragile X syndrome, and other fragile sites have been
identified that associate with ASD, such as FRA2B, FRA6A, and FRA13A [48].
5. Challenges of genetic evaluation in ASD
NGS and CMA have expanded the ability of clinical geneticists and researchers to identify
potential genetic causes of ASD. However, there are many challenges still  present in the
field  of  genetic  evaluation.  A  recent  report  in  the  American  Journal  of  Medical  Genetics
found that many children with ASD fail  to get genetic evaluation, and that parents and
medical  professionals  need to  be  better  educated about  the  potential  benefits  of  genetic
evaluation [49]. Educating parents on genetic evaluation is especially critical in light of a
recent survey of  nine parents  regarding their  child’s  participation in genetic  research in
ASD [50],  in which parents  valued having had their  child enrolled for  a  variety of  rea‐
sons, including the potential use of genetic results in tailoring intervention and in family
planning, the establishment of connections with experts in the field of ASD, and network‐
ing with other families, among others.
Even with the increased sensitivity of genetic evaluation techniques, an underlying genetic
cause of ASD is still only identified in a minority (< 25%) of ASD cases [51]. One of the major
challenges in the clinical interpretation of NGS and CMA lies in differentiating between
pathogenic and benign genetic variants identified in ASD patients. The pathogenic relevance
of the vast majority of ASD-linked genetic variants remains unknown; such variants are
frequently classified as variants of unknown significance, or VOUS. While the identification
of a genetic lesion in an existing ASD susceptibility gene or CNV locus is suggestive of a
possible genetic cause of disease, variants in these genes and CNV loci have also been observed
in seemingly unaffected individuals. Furthermore, it is important to note that, while techno‐
logical advances have expanded the ability of clinical geneticists and researchers to identify
these potential genetic causes of ASD, there is no genetic test available for the diagnosis of
ASD. A recent report proposed a means of predicting a diagnosis of ASD based on the
identification of candidate SNPs [39]. The accuracy of the predictive classifier was found to be
71.7% in individuals of Central European descent from validation datasets. However, the
accuracy of the predictive classifier fell when tested in a Han Chinese cohort, a finding that
stresses how genetic heterogeneity across populations complicates the use of such an ap‐
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proach. In addition, the overall accuracy of the predictive classifier is likely too low to serve
as an effective diagnostic tool.
A number of guidelines have already been proposed to aid clinicians and clinical geneticists
in the interpretation and reporting of CNVs. With the increasing use of high resolution NGS
technologies, similar guidelines will likely be proposed for the interpretation and reporting of
single nucleotide variants (SNVs). Furthermore, tools and prioritization schema have also been
developed to aid clinicians in the interpretation of genetic testing results. Here we discuss in
greater detail the challenges in interpreting genetic screening results in ASD cases, the
strategies that have been proposed for the interpretation and reporting of screening results,
and the resources available to aid in that interpretation.
5.1. Challenges in the interpretation of ASD genetic screening results
5.1.1. Technical limitations of NGS and CMA
As previously mentioned, as the size of the sequenced target increases, so does the poten‐
tial  number of  false-positive and false-negative variants identified [11].  Such sequencing
artifacts are particularly problematic for the detection of spontaneous, or de novo variants,
as false-positive variants would appear to be de novo in origin when they are observed in
an offspring’s genome but not in parental genomes. Furthermore, the source of DNA used
in sequencing studies can introduce sequencing artifacts.  DNA from lymphoblastoid cell
lines  from individuals  to  be  genetically  evaluated is  a  commonly used template  for  se‐
quencing;  however,  the  creation  and  culturing  of  these  cell  lines  can  introduce  genetic
changes that would appear as de novo variants when such cell lines are compared between
parents and offspring. In order to remove or reduce the possibility of artifactual results,
subsequent  variant  validation  should  be  performed.  In  the  case  of  single  gene  variants
identified by NGS, a more targeted sequencing approach limited to the gene or region of
interest would confirm the variant previously identified. In the case of CNVs identified by
NGS or CMA, a targeted detection method such as quantitative real-time PCR or FISH is
frequently used to confirm their discovery.
5.1.2. Genetic heterogeneity
While the genetic basis of many human diseases can be traced back to one or a few genes,
the genetic basis of complex neuropsychiatric disorders such as ASD has proven to be far
more complicated, with hundreds of genes and genomic loci associated with varying risks
of  disease.  The recent  utilization of  NGS and CMA approaches in genetic  evaluation of
ASD cases has led to the detection of genetic variation not only in both existing and novel
susceptibility  genes  and  genomic  loci.  However,  the  strength  of  evidence  for  many  of
these novel candidate genes or genomic loci is minimal, and some degree of replication in
follow-up studies will  be required to fully assess the relevance of many of these newly-
identified variants.
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5.1.3. Incompelete penetrance and variable expressivity
One of the major challenges in identifying potential causative genetic variation in ASD cases
lies in the fact that a potentially disruptive variant in a gene or genomic loci may not always
associate or segregate with disease. For example, a potentially pathogenic variant in a gene
may not only be present in an ASD individual, but it may also be present in seemingly
unaffected family members. Similarly, the pathogenic variant may also be observed in
seemingly unaffected individuals in the general population. This phenomenon, referred to as
incomplete penetrance, complicates the interpretation of genetic evalaution.
Alternatively, a genetic variant may result in a range of disease severity in affected individuals,
a phenomenon known as variable expressivity. For example, ~500 kb deletions and duplications
at the 16p11.2 locus are among the most heavily studied ASD-associated CNVs. However,
CNVs at this locus are also responsible for a range of other neurodevelopmental and neuro‐
psychiatric disorders, such as schizophrenia. CNVs at the 16p11.2 locus can also be inherited
from seemingly unaffected family members and have been observed in unaffected individuals
in the general population. This lack of correlation between genotype and phenotype as it relates
to ASD-associated genetic variation may be in part due to differences in gene-environment
interactions between individuals carrying such variation.
A recent report highlights some of the challenges inherent in the genetic evaluation of ASD
individuals. A putative disruptive variant in the ASD-associated SHANK3 gene was identified
in a boy with autism [52]. The variant, which was inherited from a healthy mother, was a small
insertion that would be predicted to result in a frameshift and premature stop. Based on this
evidence, as well as the relatively high penetrance of SHANK3 mutations in ASD and other
neuropsychiatric diseases, one could conclude that this variant in the SHANK3 gene was
pathogenically relevant in this autistic male. However, follow-up studies revealed that this
variant was unlikely to be present in the majority of SHANK3 transcripts due to alternative
splicing events. Furthermore, this variant was observed in 4 out of 382 control individuals
without neuropsychiatric conditions, a rate >1%. This report not only illustrates the necessity
of determining the frequency of a given potentially pathogenic variant in the general popula‐
tion but also warns against relying too heavily on computational, or in silico, predictions of the
effects of that variant on gene function.
5.2. Ethical considerations in the reporting of ASD genetic screening results
Informed consent, and the extent to which participants have been sufficiently informed as
to the purpose of a research or clinical study, has long been an issue in the field of genet‐
ic  evaluation.  For  example,  the  extent  to  which  research  findings  will  be  released  and
made available is one that participants in genetic evaluation studies should be informed
of beforehand. In some cases, the participants themselves may not be able to gain access
to  the  findings  of  genetic  evaluation.  This  is  an  issue  that  has  only  been  compounded
with the rise of NGS and CMA and subsequent explosion in the amount of genetic data
generated by these techniques.
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The sheer volume of genetic information generated by NGS and CMA not only leads to the
identification of potential genetic causes of a disease of interest, but also frequently leads to
the detection of other variants that are no directly related to the disease under investigation
but are related to other inherited human diseases. The extent to which these incidental findings
should be reported is a subject of some controversy, particularly in those situations in which
genetic predisposition to an adult-onset disease is discovered in a child being evaluated for
genetic causes of childhood developmental disorders. One such situation was described in a
recent news feature in Nature in which the family of a child who had undergone genetic testing
for developmental disability had to be informed that the child carried a genetic predisposition
to colon cancer after extensive debate between clinical geneticists and ethics reviewers as to
the extent to which such genetic information should be reported [53]. The degree to which
clinical geneticists should report incidental findings in research participants has been consid‐
ered by numerous authors [54-57], but as of yet there is not consensus. Many of these same
ethical concerns must be considered in the reporting of genetic evaluation results in individuals
with ASD.
Another consideration lies in the use of genetic evaluation to determine the recurrence risk in
the siblings of children with ASD and in family planning [50]. Given a recent estimate that the
recurrence rate of ASD in siblings may be as high as ~20% [58], the identification of inherited
variants that potentially impart susceptibility to ASD is of critical importance both in identi‐
fying at-risk siblings that have not yet begun to manifest symptoms of ASD and in making
informed decisions with regards to family planning.
5.3. Strategies for ASD genetic screening interpretation and reporting
The American College of Medicine Genetics released practice guidelines for the use of genetic
screening techniques in the evaluation of individuals with ASD in 2008 [59]. In the years that
have followed, additional practice guidleines and consensus statements discussing the use of
CMA in the genetic evaluation of ASD cases have been published [25, 26]. With its increasing
usage in the genetic evaluation of ASD cases, similar practice guidelines and consensus
statements regarding NGS will likely be forthcoming, and strategies for the interpretation of
NGS data in the evaluation of neurological diseases have recently been proposed [14]. In this
section we highlight some of the factors to consider in the interpretation of genetic screening
results in ASD cases.
5.3.1. Variant inheritance and segregation with ASD
One of the key determinants in the interpretation of ASD genetic screening results is the
mechanism of variant inheritance and how closely that variant segregates with ASD. Genetic
variation can either arise de novo or be transmitted from one or both parents. There has been
considerable interest in the ASD research community in the pathogenic relevance of de novo
variants, especially within the context of sporadic ASD cases.
As they have been subjected to less stringent evolutionary selection, de novo variants tend to
be more deleterious than inherited variants, making them excellent candidates for sporadi‐
Recent Advances in Autism Spectrum Disorders - Volume I206
cally-occurring disease [11]. An increased rate of de novo CNVs in sporadic cases compared to
familial cases has been reported [21, 60], and rare de novo CNVs at specific genomic loci were
found to associate with ASD in sporadic cases from the Simons Simplex Collection [24]. Exome
sequencing studies using ASD cohorts have reported an increased rate of de novo gene-
disrupting events (i.e. nonsense, splice-site, and frameshift mutations) in affected children
compared to their unaffected siblings [10].
Whereas ASD genetic research is increasingly focused on de novo genetic variation, it should
be remembered that the genetic basis of ASD was first established by studies demonstrating
the high heritability of the disease, a fact that illustrates the continued importance of identi‐
fying inherited genetic variation in ASD cases. A number of inherited single gene variants and
CNVs that segregate with disease in ASD families has been recently described [9, 61-64]; these
and other findings clearly demonstrate the importance of identifying inherited variants that
closely segregate with disease in affected families. It should be noted that determining the
extent of variant segregation in ASD families can be complicated by the phenotypic heteroge‐
neity that a given variant can cause from one affected family member to another. Furthermore,
a disease-causing variant may exclusively segregate with disease in males, even if the variant
does not reside on the X chromosome, as is the case with a SHANK1 mutation identified in a
four-generation ASD family [61]. Detailed family history and genetic evaluation of both
affected and unaffected family members is essential in determining the signficance of both de
novo and inherited variants in ASD cases.
5.3.2. Functional impact of variant
In addition to the mechanism of variant inheritance and variant segregation with disease,
another important consideration in interpretation of genetic screening results lies in the
functional impact of the variant. In many cases, especially with the use of high-throughput
screening technologies, variant function is predicted in silico. In the case of single gene
mutations, variation that results in disruption of gene function, such as nonsense mutations,
splice-site mutations, or frameshift mutations that introduce premature stop codons, are strong
genetic candidates, especially if such gene-disrupting variants are identified in a known ASD
suscepibility gene or a gene associated with an ASD-linked pathway. The interpretation of
missense mutations is more complicated and requires assessment of evolutionary conservation
using phyloP or Genomic Evolutionary Rate Profiling (GERP) conservation scores, as well as
scoring of the functional impact using Grantham or PolyPhen-2. However, as previously
mentioned [52], dependency on in silico predictions for variant function, even in well charac‐
terized ASD-linked genes, can lead to false conclusions. As such, experimental functional
assays are essential to accurately determine the impact of a given variant on gene expression
or function of the encoded gene product.
5.3.3. Clinical correlations of the variant with ASD
Another consideration in the interpretation of genetic screening results in ASD cases is the
degree of clinical correlation of a given variant with ASD. Hundreds of susceptibility genes
and CNV loci linked with ASD have been identified and catalogued in online genetic databases
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such as AutDB, DECIPHER, and others. The identification of a novel, potentially pathogenic
variant in one of these known susceptibility genes or CNV loci would be strong evidence for
a causal role. To a lesser extent, a novel variant in a gene in an ASD-associated pathway or a
gene previously shown by gene expression studies to be differentially regulated in ASD tissue
would be a strong candidate. Another factor to consider is the frequency of a variant of interest
in healthy control populations; the absence or significantly reduced frequency of the variant
of interest in unaffected individuals would offer strong evidence for a causal role.
5.4. Resources for ASD genetic screening interpretation
A number of online resources are available to aid clinical geneticists in the interpretation of
genetic screening results in ASD individuals. Many of these resources are aimed at differen‐
tiating between rare, potentially ASD-specific variants and benign variants observed in the
general population. In this section we will describe some of these resources in greater detail.
5.4.1. Genetic variation in control populations
Differentiating between potentially pathogenic and benign genetic variants in ASD cases
requires knowledge of the degree of genetic variation that resides within seemingly unaffected
individuals in the general population. A number of online resources, several of which are
hosted by the National Center for Biotechnology Information (NCBI) [65], have been devel‐
oped to allow clinical geneticists to visualize genetic variation identified in the general
population. The genetic variation curated in these databases can range from single nucleotide
polymorphisms to chromosomal structural variation and has proven invaluable in assessing
the potential pathogenic relevance of novel genetic variants.
5.4.1.1. dbSNP (database of single nucleotide polymorphisms)
dbSNP (http://www.ncbi.nlm.nih.gov/snp) is a public domain database hosted by NCBI
collecting a range of polymorphic genetic variation, including single nucleotide polymor‐
phisms (SNPs), small-scale multi-base deletions or insertions (also called deletion insertion
polymorphisms or DIPs), and retroposable element insertions and microsatellite repeat
variations (also called short tandem repeats or STRs) [65].
5.4.1.2. 1,000 Genomes Project
The 1,000 Genomes Project (http://www.1000genomes.org/) is a consortium employing high-
throughput NGS techniques for the purposes of characterizing over 95% of genetic variants
located in genomic regions accessible to sequencing and occurring at an allelic freuqency of
1% or higher in each of five major population groups [66].
5.4.1.3. dbVar (database of genomic structural variation)
dbVar (http://www.ncbi.nlm.nih.gov/dbvar/) is a searchable online database hosted by NCBI
containing genomic structual variation, defined by the database as inversions, balanced
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translocations, and CNVs approximately 1 kb or larger in size, that has been observed in both
case and control populations [65].
5.4.1.4. Database of Genomic Variants
The Database of Genomic Variants (http://dgvbeta.tcag.ca/dgv/app/home?ref=NCBI36/hg18)
is an curated online database hosted by the Centre for Applied Genomic that contains struc‐
tural variation, defined by the developers of the database as genomic alterations that involve
segments of DNA that are larger than 50bp, in control individuals [67]. Users can search the
database for genetic variants such as CNVs, insertions, inversions, and regions of uniparen‐
tal disomy, as well as download database contents.
5.4.2. Genotype-phenotype association
The dbGaP public repository (http://www.ncbi.nlm.nih.gov/gap/) was created by the Na‐
tional Institutes of Health for the purposes of collecting individual-level genotype and phe‐
notype data and associations between them [68]. The studies collected in dbGaP include
genome-wide association studies, sequencing and diagnostic assays, and associations be‐
tween genotype and non-clinical traits. Users can browse association results, utilize the Phe‐
notype-Genotype Integrator (PheGenI) to search for phenotypic traits linked to GWAS data,
and download data.
6. Conclusion
The development of lower-cost, high-throughput genome-wide genetic screening technolo‐
gies has revolutionized the field of genetic evaluation and now provides clinical geneticists
and researchers the opportunity to detect genetic variation in ASD individuals like never be‐
fore. In doing so, the evidence for previously identified genetic susceptibility factors will ex‐
pand, and novel ASD candidate genes and genomic loci will be identified, resulting in a
better understanding of the genetic basis of ASD. However, precautions must be taken to
ensure that genetic screening results are interpreted and reported properly.
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